Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could one month of dual blood thinners after bypass beat aspirin alone?

NCT ID NCT05997693

Disease control Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two blood thinner strategies in 700 people with chronic heart disease who are having bypass surgery. One group takes ticagrelor plus low-dose aspirin for one month, then aspirin alone; the other takes only low-dose aspirin. The goal is to see if the short dual therapy reduces death, stroke, heart attack, or graft failure over the following year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 700 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Jan 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Elective first-time CABG with use of ≥1 saphenous vein graft; * Ability to sign informed consent and comply with all study procedures, including follow-up for at least 5 years. Exclusion Criteria: * Any indication for dual antiplatelet therapy, including * Acute/recent (within 1 year) ACS (NSTE-ACS or STEMI) * Recent PCI requiring continuation of dual antiplatelet therapy after CABG * Current or anticipated use of oral anticoagulation; * Paroxysmal, persistent or permanent atrial fibrillation; * Any concomitant cardiac or non-cardiac procedure; * Planned cardiac or non-cardiac surgery within one year; * Preoperative end-organ dysfunction (dialysis, moderate to severe liver failure, respiratory failure), cancer or other non-cardiac comorbidity with a life expectancy \<5 years; * Inability to use the saphenous vein; * Contraindications to the use of aspirin; * Contraindications to the use of ticagrelor, including * Known hypersensitivity to ticagrelor * Active pathological bleeding (including, but not limited to gastrointestinal or intracranial bleeding) * History of intracranial hemorrhage * Concomitant therapy with strong CYP3A4 inhibitors (eg ketoconazole, clarithromycin, nefazodone, ritonavir, atazanavir) * Inability to undergo coronary computed tomographic angiography (CCTA); * Participating in another investigational device or drug study; * Women of childbearing potential * Any major perioperative complication including, but not limited to, stroke, TIA, MI, CABG-related bleeding (BARC type 4), sepsis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic coronary disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic coronary disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    22 sites in 6 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Anzhen Hospital

    RECRUITING

    Beijing, 100029, China

  • Center China Fuwai Hospital

    RECRUITING

    Beijing, China

  • Englewood Hospital

    RECRUITING

    Englewood, New Jersey, 07631, United States

  • Jena University Hospital

    RECRUITING

    Jena, Germany

  • Jilin Heart Hospital

    RECRUITING

    Changchun, Jilian, China

  • Johannes Kepler University Linz

    RECRUITING

    Linz, Austria

  • Klinik für Herz- und Gefäßchirurgie - Universitäts-Herzzentrum Freiburg - Bad Krozingen

    RECRUITING

    Freiburg im Breisgau, Germany

  • LMU Klinikum Campus Großhadern

    NOT_YET_RECRUITING

    München, Germany

  • Medical University Graz

    RECRUITING

    Graz, Austria

  • Medical University Innsbruck

    RECRUITING

    Innsbruck, Innsbruck, 6020, Austria

  • Medical University of Vienna

    RECRUITING

    Vienna, 1090, Austria

  • NewYork-Presbyterian: Queens Hospital

    RECRUITING

    Flushing, New York, 11355, United States

  • Robert-Bosch-Krankenhaus Stuttgart

    NOT_YET_RECRUITING

    Stuttgart, Germany

  • Ruijin Hospital: Shanghai Jiao Tong University School of Medicine

    RECRUITING

    Shanghai, China, 200023, China

  • Sahlgrenska University Hospital

    RECRUITING

    Gothenburg, 413 45, Sweden

  • Sahlgrenska University Hospital Sweden

    NOT_YET_RECRUITING

    Gothenburg, Sweden

  • Skåne University Hospital

    RECRUITING

    Malmö, 214 28, Sweden

  • University Hospital Giessen

    RECRUITING

    Giessen, 35043, Germany

  • University Hospital of Düsseldorf

    RECRUITING

    Düsseldorf, Germany

  • University of Ottawa Heart Institute

    NOT_YET_RECRUITING

    Ottawa, Ontario, K1Y 4W7, Canada

  • Weill Cornell Medicine

    RECRUITING

    New York, New York, 10065, United States

  • Westdeutsches Herz- und Gefäßzentrum Essen, Universität Duisburg-Essen

    NOT_YET_RECRUITING

    Essen, Germany